NovoCure Limited Stock News

The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regarding FDA app

One of NovoCure's late-stage clinical trials didn't turn out well. There are serious questions about the cost effectiveness of its product.

On Monday, Novocure announced a key phase 3 trial evaluating its Tumor Treating Fields (TTFields) therapy in treating platinum-resistant ovarian cancer failed to meet its primary endpoint. The company

NovoCure's treatment for ovarian cancer failed to prove it was effective in a late-stage trial. It's a big blow for a company whose business isn't in terribly great shape.

Novocure (NVCR) shares plunged 37.5% on Monday after the provider of cancer-fighting treatments reported a Phase 3 trial of its Tumor Treating Fields (TTFields) therapy for ovarian cancer patients fai

Shares of innovative biotechnology firm Novocure (NASDAQ: NVCR ) cratered badly, losing 30% on Monday morning before fading even further in the early afternoon session. Unfortunately, the company —

NovoCure's tumor treating fields therapy didn't meet the primary endpoint in a phase 3 study targeting ovarian cancer. The company's analysis pointed to a potential benefit for TTFields in treating ov

Novocure (NASDAQ:NVCR) shares are down nearly a third Monday after a Phase 3 study of its Tumor Treating Fields therapy was reported to have failed.  The stock hit a 52-week low after the company ann

Shares of Novocure Ltd. NVCR, -0.77% dropped 37% premarket on Monday after the Swiss oncology company said a late-stage trial of Tumor Treating Fields with paclitaxel failed to meet its primary endpoi

Novocure said on Monday its therapy failed in a late-stage trial to meet the main goal of improving survival rates in patients with a type of ovarian cancer.

NovoCure will soon report data from multiple late-stage trials. The company is focused on treating aggressive forms of cancer, which could open up huge opportunities for the business.

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences.

Growth stocks have roared back to life after a rough 2022. Confluent and NovoCure are two high-growth companies with attractive long-term value propositions.

NovoCure struggles to stay profitable despite having a product on the market. Penetrating its addressable market appears to be far easier said than done.

The cancer-focused biotech published its second-quarter results. These fell short of analyst expectations, unfortunately.